Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity DrugInvestors Business Daily • 09/30/26
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.Market Watch • 09/30/26
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trialCNBC • 09/30/26
A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new studyWSJ • 09/30/26
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetesPRNewsWire • 09/30/26
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitisPRNewsWire • 09/30/26
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/29/26
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetesPRNewsWire • 09/29/26
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.The Motley Fool • 09/29/26
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's MounjaroReuters • 09/29/26
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparisonPRNewsWire • 09/29/26
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparisonPRNewsWire • 09/29/26
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair LossZacks Investment Research • 09/28/26
Eli Lilly Wavered Over the Last Month: One of Wall Street's Biggest Banks Says 35% Gains Still to Come24/7 Wall Street • 09/28/26
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICsPRNewsWire • 09/28/26